SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, cash4, Peter Lynch, NewTrader2017, pharmacyman
Search This Board: 
Last Post: 5/28/2017 9:59:45 AM - Followers: 125 - Board type: Free - Posts Today: 1
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Current Report Filing (8-k) 05/22/2017 06:05:29 AM
INNV News: Current Report Filing (8-k) 05/16/2017 06:12:08 AM
INNV News: Quarterly Report (10-q) 05/15/2017 06:11:33 AM
INNV News: Current Report Filing (8-k) 05/12/2017 04:08:50 PM
INNV News: Current Report Filing (8-k) 05/09/2017 06:11:15 AM
#9455  Sticky Note Heavily shorted almost 3 Mil shares looking to cover. cash4 05/23/17 10:41:56 AM
#9167  Sticky Note 10-Q Our Products BooDog 05/15/17 07:56:30 AM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#9707   mulally, how old are your kids and where Batermere 05/28/17 09:59:45 AM
#9706   I think almost ALL of our Chartist friends Honeycomb777 05/27/17 09:16:10 PM
#9705   Benny - spot on mulally 05/27/17 11:06:17 AM
#9704   For ones that share my vision/belief that sales Honeycomb777 05/27/17 10:52:22 AM
#9702   Anybody else think these print ads are a s_Henderson 05/27/17 02:35:28 AM
#9701   I'm rooting for you, I won't get rich nFUSZmywallet 05/27/17 12:51:37 AM
#9700   Hoping to add and average down next week nFUSZmywallet 05/27/17 12:48:26 AM
#9699   STOP right there...make that 8 products getting in Honeycomb777 05/27/17 12:37:50 AM
#9698   So let's just review: Honeycomb777 05/27/17 12:23:39 AM
#9697   Why is this coming week going to be Honeycomb777 05/27/17 12:10:42 AM
#9696   I just want to point out: ABOUTTHEBENNY 05/26/17 10:43:39 PM
#9695   I'm sending my kids to college on this mulally 05/26/17 07:56:13 PM
#9693   Spot on. We all work hard for our sweetstreet 05/26/17 06:45:29 PM
#9692   Today was a good start, a lot of nFUSZmywallet 05/26/17 06:03:02 PM
#9691   Yes you're right if you're a long run. mike007 05/26/17 05:15:01 PM
#9690   I think it def hits 15-20. Not mulally 05/26/17 05:03:36 PM
#9689   let me clear my posted, the price is mike007 05/26/17 05:00:49 PM
#9688   Think ! Itz going lower. No more discount. mike007 05/26/17 04:57:07 PM
#9687   Somebody gave up enough coin to buy 55K Batermere 05/26/17 04:53:43 PM
#9686   Big buying at close. What gives? mulally 05/26/17 04:45:51 PM
#9685   Naw, my DCA was .55. Ouch. Batermere 05/26/17 04:15:17 PM
#9684   touche hope you get out with some skin TrueTrades 05/26/17 04:12:06 PM
#9683   I got you beat. I sold 500K at Batermere 05/26/17 04:09:13 PM
#9682   What a close!!!! mulally 05/26/17 04:08:10 PM
#9681   hey i got 700K sold above .13 TrueTrades 05/26/17 04:04:23 PM
#9680   Quite impressive isn't it? And the DESIGNATED IHUB Batermere 05/26/17 04:00:32 PM
#9679   Wow. Look at this late day push. sweetstreet 05/26/17 03:56:14 PM
#9678   best thing i read in weeks TrueTrades 05/26/17 03:47:53 PM
#9676   It's very simple. IT'S NOT MY JOB. It's Batermere 05/26/17 03:38:15 PM
#9673   No thanks. You would probably be the guy Batermere 05/26/17 03:28:36 PM
#9671   net margins are 14% TrueTrades 05/26/17 03:18:16 PM
#9670   Enjoy the nice long weekend...make sure to tell Honeycomb777 05/26/17 03:15:33 PM
#9669   Ouch. That hurts. BUY MORE ALERT. Batermere 05/26/17 03:13:58 PM
#9668   innv -5% TrueTrades 05/26/17 02:57:59 PM
#9667   Sure... long run...bro mike007 05/26/17 02:40:43 PM
#9666   Eager to watch this puppy close...long weekend coming, Honeycomb777 05/26/17 02:16:16 PM
#9665   Swawn - Just couldn't take the BS healthywelth 05/26/17 12:24:16 PM
#9663   Despite the naysayers I have always felt this nFUSZmywallet 05/26/17 12:02:00 PM
#9662   Who the heck would want to break into Honeycomb777 05/26/17 11:53:24 AM
#9661   Wouldn't be a bad idea, pennies for them, nFUSZmywallet 05/26/17 11:50:29 AM
#9660   HC- Just more of your wet dreams. ShawnP123 05/26/17 11:49:56 AM
#9659   Spin it how ya want but the bags Honeycomb777 05/26/17 11:40:47 AM
#9658   Long term INNV will be a huge winner. Batermere 05/26/17 11:38:36 AM
#9657   Just couldn't take the BS about a buy ShawnP123 05/26/17 11:34:43 AM
#9656   125,000 bid at .115 now let's rebuild. mulally 05/26/17 11:32:14 AM
#9655   Yep, That skyrocketed like a N. Korea missle! erdocretire 05/26/17 11:28:52 AM
#9654   Honey - Mystronagent on yahoo has been bashing GTTTR15 05/26/17 11:27:00 AM
#9653   Hey - you surfaced...I commend ya for that ! Honeycomb777 05/26/17 11:25:02 AM
#9652   The voice of FACT and REASON: Honeycomb777 05/26/17 11:20:49 AM